GlassScriptPhysician profile
Kimberley Chitko
NPI 1164559589
$13,521.41
in general payments reported to CMS, 2019-2025
50 companies · $3,679 in 2025
The $3,679 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,197 · 2023: $3,792 · 2024: $3,853 · 2025: $3,679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $300 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,836.90 |
| Consulting Fee | $300.00 |
| Education | $187.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,821.77 | 2022-2025 | Tysabri, Vumerity, Leqembi |
| Emd Serono, INC. | $1,425.86 | 2022-2025 | Mavenclad, Mavenclad |
| Alexion Pharmaceuticals, INC. | $1,144.67 | 2022-2025 | Ultomiris, Soliris |
| Abbvie INC. | $1,089.62 | 2022-2025 | |
| Lilly USA, LLC | $913.20 | 2022-2025 | Amyvid, Emgality, Kisunla |
| Pfizer INC. | $745.89 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $688.74 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $624.42 | 2022-2025 | Vyepti, Rexulti |
| Tg Therapeutics, INC. | $436.31 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $394.97 | 2023-2025 | Rytary, Crexont |
| Eisai INC. | $376.79 | 2022-2025 | |
| Harmony Biosciences LLC | $328.31 | 2023-2025 | Wakix |
| Celgene Corporation | $317.45 | 2022-2025 | Zeposia |
| Axsome Therapeutics, INC. | $314.28 | 2023-2025 | Sunosi, Symbravo |
| Sk Life Science, INC. | $218.92 | 2022-2024 | Xcopri |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $216.50 | 2022-2025 | |
| Tanabe Pharma America, INC. | $204.82 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $196.65 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $165.48 | 2022 | |
| Ucb, INC. | $147.92 | 2022-2024 | Zilbrysq |
| E.R. Squibb & Sons, L.L.C. | $122.69 | 2025 | Zeposia |
| Sumitomo Pharma America, INC. | $122.57 | 2023-2024 | Aptiom |
| Argenx US, INC. | $115.49 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Amgen INC. | $109.30 | 2023-2025 | Uplizna, Aimovig |
| Acorda Therapeutics, INC | $102.24 | 2022-2023 | Inbrija |
| Neurocrine Biosciences, INC. | $98.12 | 2022-2024 | Ingrezza, Ongentys |
| Corium, LLC | $92.32 | 2023 | Adlarity |
| Grifols USA, LLC | $90.19 | 2023-2024 | Gamunex-C |
| Genzyme Corporation | $79.86 | 2022-2025 | |
| Ani Pharmaceuticals, INC. | $78.91 | 2023 | Purified Cortrophin Gel |
| Kyowa Kirin, INC. | $65.90 | 2023 | Nourianz |
| Genentech USA, INC. | $64.64 | 2023-2025 | Ocrevus Zunovo, Ocrevus |
| Sunovion Pharmaceuticals INC. | $60.58 | 2022 | |
| Mdd US Operations, LLC | $59.38 | 2023 | Gocovri |
| Ge Healthcare | $55.20 | 2024-2025 | |
| Csl Behring | $53.75 | 2023-2025 | Hizentra |
| Neurelis, INC. | $50.70 | 2023-2025 | Valtoco |
| Mallinckrodt Hospital Products INC. | $40.65 | 2025 | Acthar |
| Merz Pharmaceuticals, LLC | $38.66 | 2023-2024 | Xeomin |
| Otsuka America Pharmaceutical, INC. | $31.66 | 2023-2024 | Nuedexta |
| Insightec,INC | $27.56 | 2022 | |
| Ns Pharma, INC. | $24.69 | 2022 | |
| Impel Pharmaceuticals INC. | $24.50 | 2023 | Trudhesa |
| Inspire Medical Systems, INC. | $24.12 | 2023 | Inspire |
| Ultragenyx Pharmaceutical INC. | $23.19 | 2024 | Dojolvi |
| Idorsia Pharmaceuticals US INC | $21.23 | 2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $18.32 | 2024 | Ponvory |
| Astrazeneca Pharmaceuticals LP | $17.88 | 2025 | Wainua |
| Catalyst Pharmaceuticals, INC. | $17.51 | 2023 | Fycompa |
| Abbott Laboratories | $17.03 | 2024 | Infinity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberley Chitko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.